Kadcyla, known as an "antibody-drug conjugate, " represents "a completely new way" to treat HER2 positive metastatic breast cancer, said Dr. Hal Barron, chief medical officer and head of global product development for Genentech.
To date, a total of 19.5 million people have received the meningococcal A conjugate vaccine manufactured by SERUM and developed through the MVP partnership.